GlassScriptPhysician profile
Nosha Farhadfar
NPI 1760819304
$116,677.78
in general payments reported to CMS, 2019-2025
22 companies · $70K in 2025
The $70K reported for 2025 was more than what 98% of Hematology & Oncology providers received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $700 · 2020: $2,910 · 2021: $970 · 2022: $5,738 · 2023: $3,130 · 2024: $33K · 2025: $70K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $64K · Consulting Fee: $22K · Travel and Lodging: $15K · Food and Beverage: $3,882 · Honoraria: $350.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $64,452.50 |
| Consulting Fee | $22,464.50 |
| Travel and Lodging | $15,210.97 |
| Food and Beverage | $3,882.03 |
| Honoraria | $350.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Incyte Corporation | $90,395.88 | 2019-2025 | Niktimvo, Jakafi, Jakafi |
| Genzyme Corporation | $10,665.73 | 2024-2025 | |
| Sanofi-Aventis U.S. LLC | $10,154.02 | 2024 | |
| National Marrow Donor Program | $2,275.84 | 2023-2025 | |
| Janssen Biotech, INC. | $1,855.81 | 2025 | |
| Jazz Pharmaceuticals INC. | $270.13 | 2023-2024 | |
| Janssen Research & Development, LLC | $194.22 | 2025 | |
| Astrazeneca Pharmaceuticals LP | $160.46 | 2024 | Calquence |
| Alexion Pharmaceuticals, INC. | $150.00 | 2019 | |
| Autolus INC | $146.47 | 2025 | |
| Celgene Corporation | $115.67 | 2019-2025 | Reblozyl, Breyanzi |
| Gilead Sciences, INC. | $80.13 | 2025 | |
| Daiichi Sankyo INC. | $58.37 | 2024 | Vanflyta |
| Janssen Scientific Affairs, LLC | $41.22 | 2025 | Darzalex, Tecvayli, Talvey |
| Adaptive Biotechnologies Corporation | $33.07 | 2025 | Clonoseq |
Show all 18 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astellas Pharma US INC | $30.92 | 2024 | Xospata |
| Legend Biotech USA INC. | $26.12 | 2025 | Carvykti |
| Glaxosmithkline, LLC. | $23.72 | 2023 | Ojjaara |
4 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Nosha Farhadfar listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.